-

Hope Biosciences Research Foundation Reports Promising Phase II Trial Results for Stem Cell Therapy in Multiple Sclerosis

SUGAR LAND, Texas--(BUSINESS WIRE)--Houston-area clinical research organization Hope Biosciences Research Foundation (HBRF) today shares positive top-line results of a Phase II clinical trial to evaluate Hope Biosciences’ adipose‑derived autologous mesenchymal stem cell therapy (HB-adMSCs) for patients with mild to moderate relapsing remitting multiple sclerosis (MS), a disease currently considered incurable that affects more than 2 million people worldwide and approximately 400,000 in the U.S.

The trial successfully met its primary endpoint, demonstrating statistically significant improvements in both physical and mental health for the treatment group compared to the placebo group. The Phase II clinical trial (NCT05116540) is a balanced randomized, double-blind, single center study that enrolled 24 participants, 12 in the treatment group and 12 in the placebo. The study mandated six intravenous infusions of 200 million stem cells over the course of 32 weeks, for a total of 1.2 billion cells. End of study was 52 weeks. The primary endpoint was the MS Quality of Life-54 Instrument, a multidimensional quality of life measure that combines general and MS-specific points related to fatigue, physical and cognitive function, sexual impairment, pain, energy, mobility, level of disability, and other considerations.

At end of study, the HB-adMSC group showed a statistically significant improvement from baseline in their Physical Health Composite Scores (p<0.0001) compared to the placebo group (p<0.4856). The effect size between the groups was large (Cohen’s d=1.23), with a significant overall treatment difference (p=0.0002). The HB-adMSC group also exhibited a significant improvement from baseline in their Mental Health Composite Scores (p<0.0042) compared to the placebo group (p<0.5724). The effect size was substantial (Cohen’s d=0.85), with a statistically significant overall treatment difference (p=0.016). Treatment was safe and tolerable in both groups. Detailed analysis is now underway.

“The results of this trial are groundbreaking for multiple sclerosis. They clearly demonstrate that high doses of fresh HB-adMSCs delivered on a regular schedule can result in consistent efficacy in a highly complex and variable condition like MS,” says Donna Chang, President, HBRF. “We believe that this positive response will translate in other autoimmune diseases in the near future.”

This research was made possible in part by the generous support of The Robert and Janice McNair Foundation. Texas-based HBRF is a 501(c)(3) nonprofit organization administered by the Greater Houston Community Foundation.

Contacts

Media: Jan Shultis
281-725-1272

Hope Biosciences Research Foundation

Details
Headquarters: Sugar Land, Texas
CEO: Donna Chang
Employees: 12
Organization: NON

Release Versions

Contacts

Media: Jan Shultis
281-725-1272

Social Media Profiles
More News From Hope Biosciences Research Foundation

Hope Biosciences Research Foundation Authorized to Begin Phase II Clinical Trial in Stem Cell Therapy for Juvenile Idiopathic Arthritis

SUGAR LAND, Texas--(BUSINESS WIRE)--Hope Biosciences Research Foundation (HBRF) has received Food and Drug Administration (FDA) Authorization to administer Hope Biosciences’ adipose-derived mesenchymal (adult) stem cells (HB-adMSCs) to pediatric patients aged 2 – 16 years old suffering from juvenile idiopathic arthritis (JIA), the first FDA authorization for work in this cell type in this condition and HBRF’s first pediatric clinical trial. JIA, formerly known as “Juvenile Rheumatoid Arthritis,...

Hope Biosciences Research Foundation Announces Topline Results of Cell Therapy Clinical Trial in Long COVID

SUGAR LAND, Texas--(BUSINESS WIRE)--Houston-area clinical research organization Hope Biosciences Research Foundation (HBRF) today shares topline results of a randomized, placebo-controlled Phase II study (NCT05126563) to evaluate Hope Biosciences’ adipose‑derived allogeneic mesenchymal stem cell therapy (HB-adMSCs) for patients with Post‑COVID‑19 syndrome. The trial enrolled 79 participants, with 39 subjects in the treatment group and 40 in the placebo group; 34 participants completed the study...

FDA Gives Green Light for Multiple Sclerosis Stem Cell Trial

SUGAR LAND, Texas--(BUSINESS WIRE)--Non-profit research organization Hope Biosciences Stem Cell Research Foundation (HBSCRF) has received FDA authorization for a randomized, double-blind, single center, Phase II clinical trial to assess the efficacy of multiple intravenous infusions of autologous adipose-derived mesenchymal stem cells in improving symptoms and quality of life in patients with mild-to-moderate multiple sclerosis (MS). Twenty-four patients will report to HBSCRF for six infusions...
Back to Newsroom